Krishna Kannan, Ph.D., MBA, is a biotechnology leader specializing in product development and synthetic biology. As Vice President of Product Development at Telesis Bio, he leads the commercialization of cutting-edge enzymatic DNA synthesis technologies, including the Gibson SOLA platform. With deep expertise in genome editing, DNA synthesis, and synthetic biology, Krishna has spearheaded the development of automated solutions for synthetic biology applications, enabling scalable and efficient workflows. His work includes pioneering genome synthesis efforts, launching innovative reagent kits, and driving strategic collaborations with industry leaders to advance molecular biology and automation technologies.